CD274 and non-small cell lung carcinoma: The one-way sensitivity analysis results suggested that the cost of pembrolizumab and cemiplimab was the most influential factor in patients with advanced NSCLC with high PD-L1 expression; however, the WTP findings were stable when the cost of pembrolizumab and cemiplimab fluctuated within a reasonable range.